Amir Englund

Amir Englund has a PhD in Cannabinoid Psychopharmacology from the IoPPN. Over the last decade he has been involved in several experimental human studies exploring the interactions of the main components of the cannabis plant in healthy volunteers. He has also been involved in clinical trials of cannabinoid treatments for psychosis.


The use of medicinal cannabis should be expanded in the UK: My view


I believe allowances should be made for individuals for whom conventional medicines have failed to try standardised cannabis preparations – where evidence suggests potential benefits. This would allow for further data collection on the efficacy and safety of cannabinoid medicines as well as give the patient another chance at symptom relief.

 

Covid-19

As an organisation, we continue to function during the developing pandemic.

We are following all government and Charity Commission guidance in respect of staff and reporting issues.

Our funding schemes remain open and we are continuing to programme our conferences planned for November 2020.